References
- Apostol G, Abi-Saab W, Kratochvil CJ, et al. (2012). Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 219:715–25
- Beconi MG, Mao A, Liu DQ, et al. (2003). Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs. Drug Metab Dispos 31:1269–77
- Beconi MG, Reed JR, Teffera Y, et al. (2007). Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35:525–32
- Chan T, Yu H, Moore A, et al. (2013). Meeting the challenge of predicting hepatic clearance of compounds slowly metbolized by cytochrome P450 using a novel hepatocyte model, HepatoPacTM. Drug Metab Dispos [Epub ahead of print]. doi: 10.1124/dmd.113.053397
- Cheng LZ, Han L, Fan J, et al. (2011). Enhanced inhibitory synaptic transmission in the spinal dorsal horn mediates antinociceptive effects of TC-2559. Mol Pain 7:56:1–13
- Gonzales D, Rennard SI, Nides M, et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc 296:47–55
- Gunduz M, Argikar UA, Baeschlin D, et al. (2010). Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab Dispos 38:361–7
- Lee CH, Zhu C, Malysz J, et al. (2011). Alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem Pharmacol 82:959–66
- Novik E, Maguire TJ, Chao P, et al. (2010). A microfluidic hepatic coculture platform for cell-based durg metabolism studies. Biochem Pharmacol 79:1036–44
- Obach RS, Reed-Hagen AE, Krueger SS, et al. (2006). Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121–30
- Rowbotham MC, Arslanian A, Nothaft W, et al. (2012). Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain 153:862–8
- Rowbotham MC, Duan WR, Thomas J, et al. (2009). A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 146:245–52
- Shaffer CL, Ryder TF, Venkatakrishnan, K, et al. (2009). Biotransformation of an α4β2 nicotinic acetylcholine receptor partial agonist in Sprague-Dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite. Drug Metab Dispos 37:1480–9
- Shaffer CL, Gunduz M, Ryder TF, O'Connell TN. (2010). Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition. Drug Metab Dispos 38:292–301
- Tong Z, Chandrasekaran A, DeMaio W, et al. (2010). Species differences in the formation of vabicaserin carbamoyl glucuronide. Drug Metab Dispos 38:581–90
- Vincent SH, Reed JR, Bergman AJ, et al. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–8
- Wang WW, Khetani SR, Krzyzewski S, et al. (2010). Assessment of a micropatterned hepatocytes coculture system to generae major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900–5